SNMMI In The News
November 20, 2012
The 2013 Imaging Outlook
Imaging Technology News
With 2013 on the horizon, ITN looks to see what issues and trends are likely to be prominent for medical imaging in the coming months. Industry experts from several professional societies and organizations gave their input about topics that will be at the forefront in 2013 and their expected impact across major industry segments.
In nuclear imaging, the U.S. Food and Drug Administration’s (FDA) approval of Eli Lilly and Co.’s Amyvid (florbetapir F-18) this past spring was one of the biggest things to come out of 2012, according to Frederic H. Fahey, DSc, president of the Society for Nuclear Medicine and Molecular Imaging (SNMMI). The first diagnostic agent to image beta-amyloid neuritic plaques in the brains of patients being evaluated for Alzheimer’s disease, Amyvid currently is only available to imaging centers in the same markets as manufacturing sites, due to the agent’s two-hour half-life.
“There are other companies involved in developing similar kinds of agents,” says Fahey. “We think there is going to be a lot of effort going [into 2013] to introduce these to the clinic. For almost 10 years, we saw no new agents in nuclear medicine, and now we see several within the last couple of years, and perhaps several more in the next year or so moving forward.”